SCHEMBL527419

SCHEMBL527419

COC(=O)c1cccc2c(=O)[nH]c(C)nc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 6/20 0.60
KDM4E B2RXH2 5/20 0.60
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
TNKS2 Q9H2K2 1/20 0.46
PKN1 Q16512 1/20 0.46
PKN2 Q16513 1/20 0.46
GAA P10253 3/20 0.44
ALDH1A1 P00352 2/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PADI4 Q9UM07 1/20 0.44
NR4A2 P43354 1/20 0.43
RIPK1 Q13546 2/20 0.43
TSHR P16473 2/20 0.43
TNKS O95271 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL527044 0.84 PARP1 (0.65) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL7477535 0.81 PARP1 (0.68) PARP1KDM4EPKN1PKN2GAA
SCHEMBL1387202 0.76 TNKS2 (0.66) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL666431 0.75 PARP1 (0.56) PARP1KDM4ETNKS2ALDH1A1HTT
SCHEMBL30401646 0.75 PARP1 (0.56) PARP1KDM4ETNKS2ALDH1A1HTT
SCHEMBL215530 0.75 PARP1 (1.00) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL29529679 0.75 PARP1 (1.00) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL1387263 0.75 PARP1 (1.00) PARP1KDM4ECYP1A2CYP2D6CYP2C9
SCHEMBL19555280 0.75 PDK2 (0.50) KDM4EPKN1PKN2GAAALDH1A1
SCHEMBL27913493 0.74 PARP1 (0.60) PARP1KDM4ECYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452480-A1 SUBSTITUTED PYRROLO[1,2- ]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Lysosomal Therapeutics Inc. (US) 2019-03-13 EP disclosed
WO-2017192929-A1 SUBSTITUTED PYRROLO[1,2-α]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2017-11-09 WO disclosed
EP-2598492-B1 BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K MERCK PATENT GMBH (DE) 2015-10-28 EP disclosed
US-8710044-B2 Bicyclic azaheterocyclic carboxamides MERCK PATENT GMBH (DE) 2014-04-29 US disclosed
EP-2598492-A1 BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K Merck Patent GmbH (DE) 2013-06-05 EP disclosed
US-20130137677-A1 Bicyclic Azaheterocyclic Carboxamides MERCK PATENT GMBH (DE) 2013-05-30 US disclosed
WO-2012013282-A1 BICYCLIC AZAHETEROCYCLIC CARBOXAMIDES AS INHIBITORS OF THE KINASE P70S6K MERCK PATENT GMBH (DE) 2012-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137677-A1 Bicyclic Azaheterocyclic Carboxamides CCNI, CCNA1, CCNA2 PARP1 91/4885KDM4E 426/4885CYP1A2 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.